Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CPT1A | P50416 | 9/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.36 |
| ▸ | CPT2 | P23786 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3781488 | 0.96 | HCRTR1 (0.39) | TP53GAAHCRTR1HCRTR2MEN1 | |
| SCHEMBL27855003 | 0.96 | HCRTR1 (0.39) | TP53GAAHCRTR1HCRTR2MEN1 | |
| SCHEMBL2454437 | 0.95 | HCRTR1 (0.38) | HCRTR1HCRTR2MEN1NPC1RAB9A | |
| SCHEMBL6167855 | 0.89 | CPT1A (0.43) | CPT1ACPT2CPT1B | |
| SCHEMBL6169351 | 0.88 | TRPV1 (0.43) | CPT1ACPT2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2363127 | 0.88 | HCRTR1 (0.41) | CPT1AHCRTR1HCRTR2CPT2NPC1 | |
| SCHEMBL13223831 | 0.86 | HCRTR1 (0.38) | TP53GAAHCRTR1HCRTR2MEN1 | |
| SCHEMBL18815729 | 0.86 | CPT1A (0.40) | CPT1AHCRTR1HCRTR2CPT2CPT1B | |
| SCHEMBL13223861 | 0.85 | KMT2A (0.43) | TP53GAAHCRTR1HCRTR2MEN1 | |
| SCHEMBL16499066 | 0.84 | GRM5 (0.36) | CPT1AHCRTR1HCRTR2CPT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100215618-A1 | NOVEL COMPOUNDS - 644 | ARROW THERAPEUTICS LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| WO-2010094977-A1 | NOVEL BIPHENYL COMPOUNDS USEFUL FOR THE TREATMENT OF HEPATITIS C | ARROW THERAPEUTICS LIMITED (GB) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100215618-A1 | NOVEL COMPOUNDS - 644 | NR1H4, HAVCR2, CYP3A4 | TP53 1159/4885GAA 2783/4885CPT1A 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.